Relmada Therapeutics (RLMD) Interest Expenses (2012 - 2015)
Relmada Therapeutics (RLMD) posted quarterly Interest Expenses of $37.9 million for Q1 2026, up 79405.86% year-over-year from N/an in Q1 2025, and up 150602.55% quarter-over-quarter from $25165.0 in Q4 2025.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Interest Expenses (2012 - 2015) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Interest Expenses for 15 consecutive years, with $37.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 79405.86% year-over-year to $37.9 million; the TTM figure through Mar 2026 stood at $37.9 million (up 27830.69% YoY), while the FY2025 annual figure was $6.9 million, up 5011.1% from the prior year.
- Interest Expenses rose to $37.9 million in Q1 2026 per RLMD's latest filing, from $25165.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $37.9 million in Q1 2026 and bottomed at $22182.0 in Q4 2023.
- Historically, Interest Expenses has averaged $4.6 million across 5 years, with a median of $44100.0 in 2023.
- Annual changes were most pronounced in 2025 — Interest Expenses plunged 99.69% — and 2026, when it surged 79405.86%.
- Relmada Therapeutics' Interest Expenses stood at $417998.0 in 2022, then slumped by 94.69% to $22182.0 in 2023, then rose by 26.22% to $27998.0 in 2024, then fell by 10.12% to $25165.0 in 2025, then surged by 150602.55% to $37.9 million in 2026.
- Business Quant data shows RLMD's Interest Expenses at $37.9 million in Q1 2026, $25165.0 in Q4 2025, and $47700.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2015 | 1,172.00 |
| Sep 30, 2015 | 1,642.00 |
| Jun 30, 2015 | 431.00 |
| Mar 31, 2015 | 125.00 |
| Dec 31, 2014 | 1,098.00 |
| Sep 30, 2014 | 3,268.00 |
| Jun 30, 2014 | 435,611.00 |
| Mar 31, 2014 | 302,440.00 |
| Feb 28, 2013 | 723.00 |
| Nov 30, 2012 | 309.00 |
| Aug 31, 2012 | 1,048.00 |
| May 31, 2012 | 2,589.00 |